Last reviewed · How we verify
Fluad and PPV23 on the different arms
This is a comparative study evaluating two different vaccines (Fluad and PPV23) administered on separate study arms to assess immunogenicity and safety in a specific population.
This is a comparative study evaluating two different vaccines (Fluad and PPV23) administered on separate study arms to assess immunogenicity and safety in a specific population. Used for Seasonal influenza prevention (Fluad), Pneumococcal disease prevention (PPV23).
At a glance
| Generic name | Fluad and PPV23 on the different arms |
|---|---|
| Sponsor | Korea University Guro Hospital |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Fluad is an inactivated influenza vaccine adjuvanted with MF59, designed to enhance immune response to seasonal influenza. PPV23 (pneumococcal polysaccharide vaccine) provides protection against 23 serotypes of Streptococcus pneumoniae. This study compares these vaccines when given on different arms rather than co-administered, likely to evaluate potential immunological interference or optimal spacing.
Approved indications
- Seasonal influenza prevention (Fluad)
- Pneumococcal disease prevention (PPV23)
Common side effects
- Injection site pain/erythema
- Myalgia
- Fatigue
- Headache
- Low-grade fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: